Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
GANX Gain Therapeutics	$1.55 +1.3%	$1.69	$0.95 ▼ $3.19	$46.01M	0.1	266,564 shs	247,488 shs
OTLK Oncobiologics	$2.13 +1.9%	$1.92	$0.87 ▼ $8.32	$70.16M	0.26	892,982 shs	1.65 million shs
RLYB Rallybio	$0.54 +6.3%	$0.42	$0.22 ▼ $1.25	$21.05M	-1.12	563,233 shs	330,748 shs
VNRX VolitionRx	$0.62 -1.1%	$0.69	$0.40 ▼ $0.94	$64.47M	1.26	193,046 shs	79,406 shs

The Next 7 Blockbuster Stocks for Growth Investors

Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
GANX Gain Therapeutics	+1.31%	+0.32%	-16.67%	-14.36%	+65.58%
OTLK Oncobiologics	+1.91%	+13.30%	-8.19%	+27.16%	-72.52%
RLYB Rallybio	+6.29%	+1.46%	+27.48%	+67.26%	-53.04%
VNRX VolitionRx	0.00%	-7.19%	-9.45%	+36.68%	+27.84%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
GANX Gain Therapeutics	2.7433 of 5 stars	3.5	5.0	2.2	0.0	0.6
OTLK Oncobiologics	2.6069 of 5 stars	3.4	4.0	3.0	0.0	0.6
RLYB Rallybio	2.5849 of 5 stars	3.0	2.0	3.2	1.7	1.3
VNRX VolitionRx	2.4905 of 5 stars	3.5	0.0	3.3	2.5	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
GANX Gain Therapeutics	3.00	Buy	$7.83	405.38% Upside
OTLK Oncobiologics	2.80	Moderate Buy	$9.60	350.70% Upside
RLYB Rallybio	2.00	Hold	$10.00	1,767.76% Upside
VNRX VolitionRx	3.00	Buy	$3.50	464.52% Upside

Current Analyst Ratings Breakdown

Latest RLYB, OTLK, GANX, and VNRX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/13/2025	GANX Gain Therapeutics	Roth Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$7.00 ➝ $6.00
7/17/2025	VNRX VolitionRx	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$5.00
7/9/2025	VNRX VolitionRx	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$5.00
7/3/2025	GANX Gain Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$8.00
6/10/2025	VNRX VolitionRx	Jones Trading Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy	$3.00
6/6/2025	OTLK Oncobiologics	Ascendiant Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$24.00 ➝ $21.00
5/20/2025	OTLK Oncobiologics	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
5/19/2025	GANX Gain Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$8.00 ➝ $8.00

(Data available from 8/14/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
GANX Gain Therapeutics	N/A	N/A	N/A	N/A	$0.28 per share	N/A
OTLK Oncobiologics	N/A	N/A	N/A	N/A	($3.09) per share	N/A
RLYB Rallybio	$640K	34.96	N/A	N/A	$1.10 per share	0.49
VNRX VolitionRx	$1.31M	49.27	N/A	N/A	($0.11) per share	-5.64

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
GANX Gain Therapeutics	-$20.41M	-$0.63	N/A	N/A	N/A	N/A	-253.21%	-146.35%	N/A
OTLK Oncobiologics	-$75.37M	-$0.91	N/A	N/A	N/A	N/A	N/A	-271.12%	N/A
RLYB Rallybio	-$57.78M	-$0.94	N/A	N/A	N/A	-5,473.33%	-71.66%	-65.06%	N/A
VNRX VolitionRx	-$35.32M	-$0.27	N/A	∞	N/A	-2,321.14%	N/A	-163.39%	N/A

Latest RLYB, OTLK, GANX, and VNRX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/12/2025	Q2 2025	GANX Gain Therapeutics	-$0.17	-$0.19	-$0.02	-$0.19	N/A	N/A
8/7/2025	Q2 2025	RLYB Rallybio	-$0.2450	-$0.22	+$0.0250	-$0.22	N/A	$0.21 million
5/15/2025	Q2 2025	OTLK Oncobiologics	-$0.55	-$0.40	+$0.15	-$1.50	$0.70 million	N/A
5/14/2025	Q1 2025	GANX Gain Therapeutics	-$0.16	-$0.16	N/A	-$0.16	$0.03 million	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
GANX Gain Therapeutics	N/A	N/A	N/A	N/A	N/A
OTLK Oncobiologics	N/A	N/A	N/A	N/A	N/A
RLYB Rallybio	N/A	N/A	N/A	N/A	N/A
VNRX VolitionRx	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
GANX Gain Therapeutics	0.05	2.22	2.22
OTLK Oncobiologics	N/A	0.72	0.57
RLYB Rallybio	N/A	9.98	14.68
VNRX VolitionRx	N/A	0.22	0.22

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
GANX Gain Therapeutics	11.97%
OTLK Oncobiologics	11.20%
RLYB Rallybio	90.34%
VNRX VolitionRx	8.09%

Insider Ownership

Company	Insider Ownership
GANX Gain Therapeutics	7.18%
OTLK Oncobiologics	4.80%
RLYB Rallybio	8.70%
VNRX VolitionRx	10.40%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
GANX Gain Therapeutics	20	30.07 million	27.91 million	Optionable
OTLK Oncobiologics	20	33.57 million	31.96 million	Optionable
RLYB Rallybio	40	41.79 million	38.15 million	Not Optionable
VNRX VolitionRx	80	103.98 million	80.80 million	Optionable

RLYB, OTLK, GANX, and VNRX Headlines

Recent News About These Companies

VolitionRx (NYSE:VNRX) Stock Price Down 4.3% - Here's What Happened

August 9, 2025 | marketbeat.com

VolitionRx Limited Schedules Second Quarter 2025 Earnings Conference Call and Business Update | ...

August 8, 2025 | gurufocus.com

VolitionRx Limited Schedules Second Quarter 2025 Earnings Conference Call and Business Update

August 8, 2025 | prnewswire.com

Insider Buying: VolitionRx Limited (NYSE:VNRX) Director Buys 78,125 Shares of Stock

August 7, 2025 | marketbeat.com

Cameron John Reynolds Buys 78,125 Shares of VolitionRx Limited (NYSE:VNRX) Stock

August 7, 2025 | marketbeat.com

VolitionRx Limited (NYSE:VNRX) Director Acquires $50,000.00 in Stock

August 7, 2025 | insidertrades.com

VolitionRx Announces Pricing of $1.2 Million Registered Direct Offering

August 4, 2025 | prnewswire.com

VolitionRx (NYSE:VNRX) Given "Buy" Rating at D. Boral Capital

July 17, 2025 | marketbeat.com

Nu.Q® Discover Expands Global Adoption and Epigenetic Innovation

July 16, 2025 | prnewswire.com

VolitionRx Limited (VNRX) - Yahoo Finance

July 11, 2025 | nz.finance.yahoo.com

Volition Announces Groundbreaking Lateral Flow Test for Point-of-Care Quantification of Nucleosomes

July 8, 2025 | prnewswire.com

Volition Announces MARS Consortium Clinical Study Suggests Nu.Q® H3.1. Concentrations are Closely Associated with Sepsis and Organ Failure

June 12, 2025 | prnewswire.com

Jones Trading Initiates Coverage of VolitionRx (VNRX) with Buy Recommendation

June 11, 2025 | msn.com

VolitionRx director Guy Innes buys $10,772 in common stock

June 5, 2025 | investing.com

Insider Buying: VolitionRx Limited (NYSE:VNRX) Director Buys 20,000 Shares of Stock

June 5, 2025 | insidertrades.com

Volition Announces Two Oral Presentations at Asian Meeting of Animal Medicine Specialties

June 4, 2025 | prnewswire.com

VolitionRX shares hold as Benchmark maintains rating

May 21, 2025 | uk.investing.com

VolitionRx Limited (AMEX:VNRX) Q1 2025 Earnings Call Transcript

May 20, 2025 | msn.com

Insider Buying: VolitionRx Limited (NYSE:VNRX) Insider Acquires 50,000 Shares of Stock

May 20, 2025 | insidertrades.com

VolitionRx Limited Announces Successful Detection of Nucleosomes in Cats

May 19, 2025 | prnewswire.com

VolitionRX aims for cash flow neutrality in 2025 as human diagnostics licensing advances

May 16, 2025 | msn.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

RLYB, OTLK, GANX, and VNRX Company Descriptions

Gain Therapeutics NASDAQ:GANX

$1.55 +0.02 (+1.31%)

Closing price 08/13/2025 04:00 PM Eastern

Extended Trading

$1.61 +0.06 (+3.81%)

As of 08/13/2025 04:11 PM Eastern

Gain Therapeutics, Inc., a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas. Its drug discovery platform Magellan discovers novel allosteric binding sites in a disease; identifies proprietary small molecules that bind these sites to modulate protein function; and treats the underlying cause of the disease. The company's lead drug candidate, GT-02287 for the treatment of GBA1 Parkinson's disease is being evaluated in a Phase I clinical trials. It also has various small molecule drug candidates, which are in the discovery, research, and preclinical stages for the treatment of Dementia with Lewy Bodies, Alzhiemer's Disease, Gaucher, GM1 Gangliosidosis, Krabbe Disease, Alpha1-Antitrypsun deficiency, and solid tumors. Gain Therapeutics, Inc. was founded in 2017 and is headquartered in Bethesda, Maryland.

Oncobiologics NASDAQ:OTLK

$2.13 +0.04 (+1.91%)

Closing price 08/13/2025 04:00 PM Eastern

Extended Trading

$2.17 +0.04 (+1.88%)

As of 08/13/2025 07:51 PM Eastern

Outlook Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration and license agreements with BioLexis Pte. Ltd. and Zhejiang Huahai Pharmaceutical Co., Ltd. The company was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in November 2018. Outlook Therapeutics, Inc. was incorporated in 2010 and is based in Iselin, New Jersey.

Rallybio NASDAQ:RLYB

$0.54 +0.03 (+6.29%)

Closing price 08/13/2025 04:00 PM Eastern

Extended Trading

$0.52 -0.01 (-2.32%)

As of 08/13/2025 05:35 PM Eastern

Rallybio Corporation, a clinical-stage biotechnology company, engages in development and commercialization of life-transforming therapies for patients suffering from severe and rare diseases. Its lead product candidate is RLYB212, a monoclonal anti-HPA-1a antibody that has completed Phase I clinical trial for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT); and RLYB211 for the prevention of FNAIT. The company is also developing RLYB114, a pegylated complement factor 5 (C5)-targeted Affibody molecule in preclinical development for the treatment of complement-mediated ophthalmic diseases; RLYB116, an inhibitor of complement component 5 (C5) to treat several diseases of complement dysregulation which has completed phase 1 trial; and RLYB331, a preclinical antibody, for the treatment of severe anemia with ineffective erythropoiesis and iron overload. It entered into a strategic alliance with AbCellera to discover, develop, and commercialize novel antibody-based therapeutics for rare diseases. Rallybio has collaboration with Exscientia for the development of small molecule therapeutics for rare diseases; and collaboration agreement with Johnson & Johnson to provide pregnant individuals therapeutic solutions at risk of fetal and neonatal alloimmune thrombocytopenia. The company was founded in 2018 and is headquartered in New Haven, Connecticut.

VolitionRx NYSE:VNRX

$0.62 -0.01 (-1.15%)

Closing price 08/13/2025 04:00 PM Eastern

Extended Trading

$0.62 0.00 (-0.32%)

As of 08/13/2025 06:18 PM Eastern

VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection; and Nu.Q Discover, a solution to profiling nucleosomes. VolitionRx Limited is based in Henderson, Nevada.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time